Organised in two strategic business units, Boehringer Ingelheim Animal Health delivers a large and innovative portfolio of products and services to prevent disease and improve the health and productivity of animals around the world.
Member of the Boehringer Ingelheim Board of Managing Directors
Global Headquarters in
A focused and comprehensive Corporate Responsibility approach, aligned with our strategy and addressing our most pressing sustainability challenges: disease emergence, protein demand, stronger links with pets and environmental degradation.
Create a healthy and mutually beneficial human-animal bond
Expand access to responsible animal healthcare to promote food security
Care for the planet and take effective steps to minimize our environmental footprint
A family-owned company with 28 employees, headquartered in Ingelheim, Germany was founded by Albert Boehringer.
Merieux founded the Institut Biologique Mérieux (Mérieux Biological Institute), in Lyon, France. This early vaccine research and production center was the starting point for the animal health endeavors that would one day become the company Merial.
Boehringer Ingelheim’s Animal Health division was established as the company takes over Pfizer’s veterinary program.
Merial was created through the merger of Rhône Mérieux (Rhône-Poulenc, France) and MSD AgVet (Merck & Co, US)
Merial becomes a wholly-owned subsidiary of Sanofi.
Boehringer Ingelheim enters into exclusive negotiations with Sanofi consisting of a strategic exchange of their consumer healthcare business for Merial.
Two complementary companies, Boehringer Ingelheim and Merial, unite through a passion for animals and a joint history of integrity, quality and trust.